Afimkibart

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Rheumatoid ArthritisAtopic DermatitisUlcerative ColitisCrohn's Disease

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

1

Afimkibart

Roche

Phase 3

22

Actemra

Roche

Preclinical

1183

Cimzia

UCB

Preclinical

304

Enbrel

IImmunex

Preclinical

645

Actos

Takeda

Preclinical

26

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

77

Rituxan

Pfizer

Preclinical

78

Velcade

SShilpa Grover, MD, MPH

Preclinical

29

Certolizumab

Johnson & Johnson

Preclinical

310

Voltaren

CCerimon Pharmaceuticals

Preclinical

—Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Crohn's Disease4 trials

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease

Recruiting·Roche·Phase 3·NCT07298421·100 enrolled

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

Recruiting·Roche·Phase 3·NCT06819891·425 enrolled

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

Recruiting·Roche·Phase 3·NCT06819878·600 enrolled

Show 1 more trial

A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease

Active, not recruiting·Roche·Phase 2·NCT05910528·21 enrolled

Ulcerative Colitis2 trials

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting·Roche·Phase 3·NCT06589986·400 enrolled

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting·Roche·Phase 1·NCT07665723·25 enrolled

Atopic Dermatitis2 trials

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Recruiting·Roche·Phase 2·NCT06863961·160 enrolled

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Recruiting·Roche·Phase 2·NCT07223697·120 enrolled

Moderately to Severely Active Ulcerative Colitis2 trials

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting·Roche·Phase 3·NCT06588855·350 enrolled

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years With Moderately to Severely Active Ulcerative Colitis

Recruiting·Roche·Phase 3·NCT07158242·100 enrolled

Rheumatoid Arthritis2 trials

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors

Recruiting·Roche·Phase 2·NCT07137598·160 enrolled

An Extension Study to Evaluate the Long-term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Rheumatoid Arthritis Who Participated in Previous Afimkibart Clinical Trials

Recruiting·Roche·Phase 2·NCT07620392·120 enrolled

Details

Drug Info

Related News